search
Back to results

The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
Training and liraglutide
Training and placebo
Sponsored by
Tina Vilsboll
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring GLP-1, Training, Exercise, Type 2 Diabetes

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Informed oral and written consent
  • Diagnosed with type 2 diabetes according to the criteria of the WHO
  • HbA1C: 7-11% (doing treatment with diet and/or metformin)
  • Age >18 years
  • BMI >25 kg/m2 <40 kg/m2
  • Negative islet cell antibodies (ICA) and glutamate decarboxylase 65 (GAD- 65) autoantibodies

Exclusion Criteria:

  • Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures.
  • Subjects treated with sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors, insulin or glitazones
  • Ongoing abuse of alcohol or narcotics
  • Impaired hepatic function (liver transaminases >2 times upper normal limit)
  • Impaired renal function (se-creatinine >150μM and/or albuminuria)
  • Cardiac problems defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris and/or myocardial infarction within the last 12 months
  • Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >100 mmHg)
  • Anaemia
  • Any condition that the investigators feels would interfere with trial participation
  • Receiving any investigational drug within the last 3 months

Sites / Locations

  • Department of Internal Medicine, Gentofte Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Training and liraglutide

Training and placebo

Arm Description

Treatment with both training and liraglutide for 16 weeks

Treatment wiht both training and placebo for 16 weeks

Outcomes

Primary Outcome Measures

HbA1c
Change in HbA1c from baseline to 16 weeks. Glycated haemoglobin (HbA1c) is a form of haemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time (12 weeks).

Secondary Outcome Measures

Maximal oxygen uptake (VO2peak)
Changes in VO2peak from baseline to 16 weeks
Body weight
Changes in body weight from baseline to 16 weeks evaluated by a full body DEXA scan
Blood pressure
Changes in blood pressure from baseline to 16 weeks
Glycaemic control
Changes in overall glycaemic control parameters, insulin sensitivity and beta cell function evaluated by The Homeostasis Model Assessment (HOMA) and incretin hormones response
Meal test
The changes in the postprandial response of incretin hormones, insulin and glucose, glucagon and the microvascular blood flow will be evaluated. Changes in blood leves of triglycerides and cholesterol.
Myocardial echocardiography

Full Information

First Posted
October 19, 2011
Last Updated
May 28, 2015
Sponsor
Tina Vilsboll
search

1. Study Identification

Unique Protocol Identification Number
NCT01455441
Brief Title
The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes
Official Title
Does the GLP-1 Receptor Agonist (Victoza®) Improve the Metabolic Response to Physical Training in Patients With Type 2 Diabetes?
Study Type
Interventional

2. Study Status

Record Verification Date
May 2015
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Tina Vilsboll

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of this study is to investigate the effects of physical training in patients with type 2 diabetes during treatment with the GLP-1 receptor agonist liraglutide (Victoza®) in a 16-weeks double-blinded, randomized placebo-controlled clinical trial. Hypothesis: Physical training leads to better metabolic control in type 2 diabetic patients when training is combined with liraglutide (Victoza®) treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes
Keywords
GLP-1, Training, Exercise, Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Training and liraglutide
Arm Type
Active Comparator
Arm Description
Treatment with both training and liraglutide for 16 weeks
Arm Title
Training and placebo
Arm Type
Placebo Comparator
Arm Description
Treatment wiht both training and placebo for 16 weeks
Intervention Type
Other
Intervention Name(s)
Training and liraglutide
Intervention Type
Other
Intervention Name(s)
Training and placebo
Primary Outcome Measure Information:
Title
HbA1c
Description
Change in HbA1c from baseline to 16 weeks. Glycated haemoglobin (HbA1c) is a form of haemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time (12 weeks).
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Maximal oxygen uptake (VO2peak)
Description
Changes in VO2peak from baseline to 16 weeks
Time Frame
16 weeks
Title
Body weight
Description
Changes in body weight from baseline to 16 weeks evaluated by a full body DEXA scan
Time Frame
16 weeks
Title
Blood pressure
Description
Changes in blood pressure from baseline to 16 weeks
Time Frame
16 weeks
Title
Glycaemic control
Description
Changes in overall glycaemic control parameters, insulin sensitivity and beta cell function evaluated by The Homeostasis Model Assessment (HOMA) and incretin hormones response
Time Frame
16 weeks
Title
Meal test
Description
The changes in the postprandial response of incretin hormones, insulin and glucose, glucagon and the microvascular blood flow will be evaluated. Changes in blood leves of triglycerides and cholesterol.
Time Frame
16 weeks
Title
Myocardial echocardiography
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Informed oral and written consent Diagnosed with type 2 diabetes according to the criteria of the WHO HbA1C: 7-11% (doing treatment with diet and/or metformin) Age >18 years BMI >25 kg/m2 <40 kg/m2 Negative islet cell antibodies (ICA) and glutamate decarboxylase 65 (GAD- 65) autoantibodies Exclusion Criteria: Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures. Subjects treated with sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors, insulin or glitazones Ongoing abuse of alcohol or narcotics Impaired hepatic function (liver transaminases >2 times upper normal limit) Impaired renal function (se-creatinine >150μM and/or albuminuria) Cardiac problems defined as decompensated heart failure (NYHA class III or IV), unstable angina pectoris and/or myocardial infarction within the last 12 months Uncontrolled hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >100 mmHg) Anaemia Any condition that the investigators feels would interfere with trial participation Receiving any investigational drug within the last 3 months
Facility Information:
Facility Name
Department of Internal Medicine, Gentofte Hospital
City
Hellerup
ZIP/Postal Code
2900
Country
Denmark

12. IPD Sharing Statement

Learn more about this trial

The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes

We'll reach out to this number within 24 hrs